Drug Trial Radar · NCT07462130
An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)
Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
74
Planned (sponsor's estimate)
Start
Mar 1, 2026
Primary completion
May 31, 2027
Study completion Mar 30, 2028
Sponsor
- Lead sponsor
- Nanjing Chia-tai Tianqing PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Mar 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicentre, Phase Ib/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of NTB003 in Participants with Thyroid Eye Disease
Conditions
- Thyroid Eye Disease
Interventions
NTB003Drug
NTB003 dose 1 administered SC injection every 4 weeks.
NTB003Drug
NTB003 dose 2 administered SC injection every 4 weeks.
NTB003Drug
NTB003 dose 3 administered SC injection every 4 weeks.
NTB003 and PlaceboDrug
Drug:NTB003 subcutaneous injection Drug: Placebo subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proptosis Responder Rate in the study eyeTime frame: Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.